Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 73, No 1 (2022)
Original paper
Submitted: 2021-09-11
Accepted: 2021-10-14
Published online: 2022-01-31
View PDF Download PDF file
Get Citation

Association of chemotactic cytokine receptor 5 (CCR5) gene polymorphism (59029 A/G, rs1799987) with diabetic kidney disease in patients with type 2 diabetes from Poland

Patrycja Pokrzywnicka1, Hanna Kwiendacz1, Katarzyna Nabrdalik1, Weronika Hajzler2, Piotr Adamczyk3, Dariusz Moczulski4, Wanda Trautsolt1, Władysław Grzeszczak†1, Janusz Gumprecht1
DOI: 10.5603/EP.a2022.0001
·
Pubmed: 35119091
·
Endokrynol Pol 2022;73(1):103-109.
Affiliations
  1. Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  2. Doctoral School, Department of Paediatric Haematology and Oncology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
  3. Department of Paediatrics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
  4. Department of Internal Medicine and Nephrodiabetology, Medical University of Łodz, Poland

open access

Vol 73, No 1 (2022)
Original Paper
Submitted: 2021-09-11
Accepted: 2021-10-14
Published online: 2022-01-31

Abstract

Introduction: Diabetic kidney disease (DKD) pathogenesis is multifactorial and is a combination of metabolic, genetic, and environmental factors. Due to a long period of asymptomatic course, it is often diagnosed late when advanced stages of the disease are present. Among patients with diabetes, the presence of chemotactic cytokine receptor 5 (CCR5) gene polymorphism is suspected to be associated with the risk of DKD occurrence; however, the results of the research conducted so far are inconclusive. The aim of this study was to evaluate the CCR5 gene polymorphism (rs1799987, 59029 A/G) association with DKD among patients with type 2 diabetes mellitus (T2DM), who are residents of the Upper Silesia region of Poland.

Material and methods: CCR5 gene polymorphism (rs1799987, 59029 A/G) was assessed among consecutive patients with type 2 diabetes mellitus (T2DM) treated in a single outpatient diabetology clinic in Upper Silesia, Poland. Its association with DKD was examined. Additionally, selected clinical and demographic data were included in the analysis.

Results: Among 467 eligible study patients, there was no association between examined CCR5 gene polymorphism and the presence of DKD in relation both to the American Diabetes Association definition (p = 0.6) and to the National Kidney Foundation definition (p = 0.3) of this complication.

Conclusion: The presented study did not confirm the association between the examined gene polymorphism and the risk of DKD; further studies in this area are needed in order to establish or explicitly exclude this association.

 

Abstract

Introduction: Diabetic kidney disease (DKD) pathogenesis is multifactorial and is a combination of metabolic, genetic, and environmental factors. Due to a long period of asymptomatic course, it is often diagnosed late when advanced stages of the disease are present. Among patients with diabetes, the presence of chemotactic cytokine receptor 5 (CCR5) gene polymorphism is suspected to be associated with the risk of DKD occurrence; however, the results of the research conducted so far are inconclusive. The aim of this study was to evaluate the CCR5 gene polymorphism (rs1799987, 59029 A/G) association with DKD among patients with type 2 diabetes mellitus (T2DM), who are residents of the Upper Silesia region of Poland.

Material and methods: CCR5 gene polymorphism (rs1799987, 59029 A/G) was assessed among consecutive patients with type 2 diabetes mellitus (T2DM) treated in a single outpatient diabetology clinic in Upper Silesia, Poland. Its association with DKD was examined. Additionally, selected clinical and demographic data were included in the analysis.

Results: Among 467 eligible study patients, there was no association between examined CCR5 gene polymorphism and the presence of DKD in relation both to the American Diabetes Association definition (p = 0.6) and to the National Kidney Foundation definition (p = 0.3) of this complication.

Conclusion: The presented study did not confirm the association between the examined gene polymorphism and the risk of DKD; further studies in this area are needed in order to establish or explicitly exclude this association.

 

Full Text:

View PDF Download PDF file
Get Citation

Keywords

diabetes mellitus type 2; diabetic kidney disease; CCR5; gene; polymorphism

About this article
Title

Association of chemotactic cytokine receptor 5 (CCR5) gene polymorphism (59029 A/G, rs1799987) with diabetic kidney disease in patients with type 2 diabetes from Poland

Journal

Endokrynologia Polska

Issue

Vol 73, No 1 (2022)

Article type

Original paper

Pages

103-109

Published online

2022-01-31

Page views

5837

Article views/downloads

485

DOI

10.5603/EP.a2022.0001

Pubmed

35119091

Bibliographic record

Endokrynol Pol 2022;73(1):103-109.

Keywords

diabetes mellitus type 2
diabetic kidney disease
CCR5
gene
polymorphism

Authors

Patrycja Pokrzywnicka
Hanna Kwiendacz
Katarzyna Nabrdalik
Weronika Hajzler
Piotr Adamczyk
Dariusz Moczulski
Wanda Trautsolt
Władysław Grzeszczak†
Janusz Gumprecht

References (39)
  1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017; 12(12): 2032–2045.
    CrossRefPubMed
  2. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl (2011). 2018; 8(1): 2–7.
    CrossRefPubMed
  3. Matoba K, Takeda Y, Nagai Y, et al. Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease. Int J Mol Sci. 2019; 20(14).
    CrossRefPubMed
  4. Zheng Z, Zheng F. Immune Cells and Inflammation in Diabetic Nephropathy. J Diabetes Res. 2016; 2016: 1841690.
    CrossRefPubMed
  5. Tesch GH. Diabetic nephropathy - is this an immune disorder? Clin Sci (Lond). 2017; 131(16): 2183–2199.
    CrossRefPubMed
  6. Cavalera M, Frangogiannis NG. Targeting the chemokines in cardiac repair. Curr Pharm Des. 2014; 20(12): 1971–1979.
    CrossRefPubMed
  7. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal. 2004; 16(11): 1201–1210.
    CrossRefPubMed
  8. Oo Z, Barrios CS, Castillo L, et al. High levels of CC-chemokine expression and downregulated levels of CCR5 during HIV-1/HTLV-1 and HIV-1/HTLV-2 coinfections. J Med Virol. 2015; 87(5): 790–797.
    CrossRefPubMed
  9. Leach K, Charlton SJ, Strange PG. Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5. Biochem Pharmacol. 2007; 74(6): 881–890.
    CrossRefPubMed
  10. Jin J, Colin P, Staropoli I, et al. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol Chem. 2014; 289(27): 19042–19052.
    CrossRefPubMed
  11. Navratilova Z. Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006; 150(2): 191–204.
    CrossRefPubMed
  12. Martinson JJ, Chapman NH, Rees DC, et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet. 1997; 16(1): 100–103.
    CrossRefPubMed
  13. Blanpain C, Libert F, Vassart G, et al. CCR5 and HIV Infection. Recept Channels. 2011; 8(1): 19–31.
    CrossRefPubMed
  14. Yang B, Houlberg K, Millward A, et al. Polymorphisms of chemokine and chemokine receptor genes in Type 1 diabetes mellitus and its complications. Cytokine. 2004; 26(3): 114–121.
    CrossRefPubMed
  15. Mlynarski WM, Placha GP, Wolkow PP, et al. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5): a sex-specific effect. Diabetes. 2005; 54(11): 3331–3335.
    CrossRefPubMed
  16. Pettigrew KA, McKnight AJ, Patterson CC, et al. Resequencing of the CCL5 and CCR5 genes and investigation of variants for association with diabetic nephropathy. J Hum Genet. 2010; 55(4): 248–251.
    CrossRefPubMed
  17. Nakajima K, Tanaka Y, Nomiyama T, et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care. 2003; 26(3): 892–898.
    CrossRefPubMed
  18. Ahluwalia TS, Khullar M, Ahuja M, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One. 2009; 4(4): e5168.
    CrossRefPubMed
  19. Buraczynska M, Zukowski P, Wacinski P, et al. Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes. Cytokine. 2012; 58(2): 213–217.
    CrossRefPubMed
  20. Bagci B, Bagci G, Huzmeli C, et al. Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis. Int Urol Nephrol. 2016; 48(7): 1163–1170.
    CrossRefPubMed
  21. Yahya MJ, Ismail PB, Nordin NB, et al. Association of CCL2, CCR5, ELMO1, and IL8 Polymorphism with Diabetic Nephropathy in Malaysian Type 2 Diabetic Patients. Int J Chronic Dis. 2019; 2019: 2053015.
    CrossRefPubMed
  22. Yadav AK, Kumar V, Dutta P, et al. Variations in CCR5, but not HFE, ELMO1, or SLC12A3, are associated with susceptibility to kidney disease in north Indian individuals with type 2 diabetes. J Diabetes. 2014; 6(6): 547–555.
    CrossRefPubMed
  23. Mokubo A, Tanaka Y, Nakajima K, et al. Chemotactic cytokine receptor 5 (CCR5) gene promoter polymorphism (59029A/G) is associated with diabetic nephropathy in Japanese patients with type 2 diabetes: a 10-year longitudinal study. Diabetes Res Clin Pract. 2006; 73(1): 89–94.
    CrossRefPubMed
  24. Kwiendacz H, Nabrdalik K, Adamczyk P, et al. Association of single nucleotide polymorphism (rs741301) of the ELMO1 gene with diabetic kidney disease in Polish patients with type 2 diabetes: a pilot study. Endokrynol Pol. 2020; 71(1): 66–72.
    CrossRefPubMed
  25. Cunningham A, Benediktsson H, Muruve DA, et al. Trends in Biopsy-Based Diagnosis of Kidney Disease: A Population Study. Can J Kidney Health Dis. 2018; 5: 2054358118799690.
    CrossRefPubMed
  26. Lorenzo-Medina M, De-La-Iglesia S, Ropero P, et al. Effect of hemoglobin Porto Alegre on glycated hemoglobin (HbA(1c)) measurement with the HA-8160 high performance liquid chromatography method. Clin Chem Lab Med. 2013; 51(10): e247–e249.
    CrossRefPubMed
  27. Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe-what does it stand for? NDT Plus. 2011; 4(2): 83–86.
    CrossRefPubMed
  28. Shahbaz H, Gupta M. Creatinine Clearance. StatPearls Publishing , Treasure Island 2021: StatPearls.
  29. McKnight AJ, Woodman AM, Parkkonen M, et al. Warren 3/UK GoKinD Study Group. Investigation of DNA polymorphisms in SMAD genes for genetic predisposition to diabetic nephropathy in patients with type 1 diabetes mellitus. Diabetologia. 2009; 52(5): 844–849.
    CrossRefPubMed
  30. Prasad P, Tiwari AK, Kumar KM, et al. Association of TGFbeta1, TNFalpha, CCR2 and CCR5 gene polymorphisms in type-2 diabetes and renal insufficiency among Asian Indians. BMC Med Genet. 2007; 8: 20.
    CrossRefPubMed
  31. Cao M, Tian Z, Zhang L, et al. Effects of 59029G/A polymorphism on the risk to diabetic nephropathy. Oncotarget. 2017; 8(63): 106926–106934.
    CrossRefPubMed
  32. Tziastoudi M, Stefanidis I, Hadjigeorgiou GM, et al. A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy. Clin Kidney J. 2017; 10(3): 293–300.
    CrossRefPubMed
  33. Nazir N, Siddiqui K, Al-Qasim S, et al. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. BMC Med Genet. 2014; 15: 103.
    CrossRefPubMed
  34. Zhang Z, Zhang X, Dong J, et al. Association of chemokine ligand 5/chemokine receptor 5 gene promoter polymorphisms with diabetic microvascular complications: A meta-analysis. J Diabetes Investig. 2016; 7(2): 212–218.
    CrossRefPubMed
  35. Fuchsberger C, Flannick J, Teslovich TM, et al. The genetic architecture of type 2 diabetes. Nature. 2016; 536(7614): 41–47.
    CrossRefPubMed
  36. Bhatnagar A. Environmental Determinants of Cardiovascular Disease. Circ Res. 2017; 121(2): 162–180.
    CrossRefPubMed
  37. Marx N, Davies M, Grant P, et al. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes Endocrinol. 2021; 9(1): 46–52.
    CrossRefPubMed
  38. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Can J Cardiol. 2018; 34(5): 575–584.
    CrossRefPubMed
  39. Matosin N, Frank E, Engel M, et al. Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Dis Model Mech. 2014; 7(2): 171–173.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl